第 17 屆國家新創獎及2022「德國百靈佳殷格翰生醫新創獨角獸Grass Roots支持計畫」-「ADAM9 抑制劑作為新穎抗胰臟癌藥物」

胰臟癌90%為KRAS 突變，如何有效標靶多種 KRAS 突變型，仍為臨床痛點。本團隊研究發現ADAM9調控KRAS的新機轉，研發出ADAM9抑制劑，可促進KRAS蛋白分解，作為廣效型KRAS抑制劑，能廣泛應用於胰臟癌治療。ADAM9 抑制劑合併化療藥 Gemcitabine，可強化療效，避免抗藥性，兼具治療安全性，達成根除腫瘤的最佳目標。此小分子藥物開發已獲得 ADAM9 抑制劑核心結構和免疫調節應用等多國專利。研究成果已刊登於國際期刊Nature Cancer 2024。此ADAM9抑制劑亦可擴大應用於「肺癌」與「大腸癌」治療。

Pancreatic cancer is driven by KRAS mutations in 90% of cases, and effectively targeting multiple KRAS mutations remains a clinical challenge. Our research team has discovered a new mechanism by which ADAM9 regulates KRAS, leading to the development of an ADAM9 inhibitor. This inhibitor promotes the degradation of KRAS protein and acts as a broad-spectrum KRAS inhibitor, offering the potential for widespread application in pancreatic cancer treatment. Combining the ADAM9 inhibitor with the chemotherapy drug Gemcitabine enhances treatment efficacy, reduces drug resistance, and ensures therapeutic safety, aiming to achieve the best outcome of tumor eradication. This small molecule drug development has already secured multiple international patents, including the core structure of the ADAM9 inhibitor and its application in immune modulation. The research findings were published in Nature Cancer in 2024. Furthermore, the ADAM9 inhibitor has potential applications in the treatment of lung and colorectal cancers.

團隊成員包佘玉萍教授、吳永昌教授、楊顓丞、葉俊杰醫師、吳恒祥副教授、鄭維中教授、黃裕鍇、郭婷婷